Novo Nordisk to cap insulin prices in Minnesota settlement
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
ST. PAUL, Minn. – Minnesota Attorney General Keith Ellison settled with insulin manufacturers Eli Lilly, Sanofi, and Novo ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Eli Lilly and Company discovers ... Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and ...
Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback